These cancers include frequently diagnosed cancers, such as colorectal cancer, breast cancer, and lung cancer, in which the absence or low expression of FKN/CX3CR1 in tumor tissue is a poor prognostic factor associated with an increased risk of metastatic progression. This evidence concerns the gene CX3CR1 and breast carcinoma.